Development of new therapies for the prevention and
treatment of prostate cancer bone metastasis depends on understanding the dynamic reciprocal interactions between prostate cancer cells and the bone microenvironment.
«Not only could the test have a major impact
on treatment of prostate cancer, but it could also be adapted to open up the possibility of precision medicine to patients with other types of cancer as well.»
Presenting these results at the 3rd ESTRO Forum in Barcelona, Spain, today (Monday) Professor James Morris, from the Department of Radiation Oncology, Vancouver Cancer Centre, British Columbia Cancer Agency (BCCA), Vancouver, Canada, will say that the ASCENDE - RT1 trial is the first and only existing trial comparing low - dose - rate prostate brachytherapy (LDR - PB) for the
curative treatment of prostate cancer with any other method of radiation therapy delivery.
Since smoking
after treatment of prostate cancer increases the risk of cancer recurrence and second cancers, primary care clinicians should assess for tobacco use and offer or refer survivors to cessation counseling and resources.
Stephen Jesson acted for a claimant seeking compensation in light of the alleged delay in diagnosis of cancer, and is acting in a group claim filed against a consultant urological surgeon for alleged
improper treatment of prostate cancer.
Despite complications sometimes more severe than with standard radiation therapy — and costs that are much higher for taxpayers, patients and insurers — proton beam therapy is heavily marketed
for treatment of prostate cancer.
Sir Harpal Kumar, Cancer Research UK's chief executive, said: «These results could transform
the treatment of prostate cancer.
A patent has been filed for these results, which open new avenues for
the treatment of prostate cancer, and are published in Nature Communications on January 12, 2016.
«These results emphasize the potential utility of developing metabolic - targeted therapies directed toward this signaling cascade for
the treatment of prostate cancer.
Hormone therapy is used for
treatment of prostate cancer to block the production of androgens, or male sex hormones.
«African - Americans experience longer delays between diagnosis and
treatment of prostate cancer.»
Using a dose chosen for each compound individually based on the clinically relevant maximum plasma concentration, the scientists found a strong synergistic interaction between flutamide, a drug approved for
the treatment of prostate cancer, and phenprocoumon (PPC), an anti-thrombosis compound.
Prostate specific antigen (PSA) screening has enhanced the early diagnosis and
treatment of prostate cancer.
These are the words of a core statement from a study, recently published in the highly respected journal «The Lancet Oncology», which was set up based on collaboration between the world's leading centres for the research and
treatment of prostate cancer.
While this offers more flexibility and freedom of movement in how the radiation beam is delivered, this is not necessary for
the treatment of prostate cancer.
In
the treatment of prostate cancer, by contrast, many physicians routinely address concerns about sexual function.
For 1 life saved, more than 20 overdiagnosed In the new study, the researchers examined age - specific prostate cancer incidence and treatment data to figure out the effect of PSA screening on the diagnosis and
treatment of prostate cancer.
Researchers have stated that men undergoing testosterone reduction therapy (very different from testosterone replacement therapy, which is what we provide) for
the treatment of prostate cancer experienced more serious and more rapid memory loss, strongly resembling the memory difficulties associated with Alzheimer's and dementia.
Next I was offered an experimental injectable drug, Lupron, which is used to decrease the body's production of both male and female hormones and is commonly prescribed for
the treatment of prostate cancer.
Not really so benign... With a focus on men's health, Dr Philip Rouchotas MSc, ND discusses the important role of natural medicine in the prevention of prostate cancer, as well as how natural medicines can complement and support conventional therapies in
the treatment of prostate cancer.
Australia About Blog Australian Prostate Cancer is dedicated to improving lives through vital research into the prevention, management &
treatment of prostate cancer.
A clinical professor of medicine at Harvard Medical School, he also maintains an active clinical practice at Beth Israel Deaconess Medical Center, and has dedicated his career to the development of new therapies for
the treatment of prostate cancer.
Australia About Blog Australian Prostate Cancer is dedicated to improving lives through vital research into the prevention, management &
treatment of prostate cancer.
A clinical professor of medicine at Harvard Medical School, he also maintains an active clinical practice at Beth Israel Deaconess Medical Center, and has dedicated his career to the development of new therapies for
the treatment of prostate cancer.
A clinical professor of medicine at Harvard Medical School, he also maintains an active clinical practice at Beth Israel Deaconess Medical Center, and has dedicated his career to the development of new therapies for
the treatment of prostate cancer.
Australia About Blog Australian Prostate Cancer is dedicated to improving lives through vital research into the prevention, management &
treatment of prostate cancer.
Australia About Blog Australian Prostate Cancer is dedicated to improving lives through vital research into the prevention, management &
treatment of prostate cancer.
A clinical professor of medicine at Harvard Medical School, he also maintains an active clinical practice at Beth Israel Deaconess Medical Center, and has dedicated his career to the development of new therapies for
the treatment of prostate cancer.
Australia About Blog Australian Prostate Cancer is dedicated to improving lives through vital research into the prevention, management &
treatment of prostate cancer.
A clinical professor of medicine at Harvard Medical School, he also maintains an active clinical practice at Beth Israel Deaconess Medical Center, and has dedicated his career to the development of new therapies for
the treatment of prostate cancer.